Physician profile
Kenneth Lee
NPI 1023195112
$11,229.72
in general payments reported to CMS, 2019-2025
11 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,159 · 2020: $97.87 · 2021: $550 · 2022: $764 · 2023: $158 · 2024: $172 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $9,064.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $1,030.14 | 2021-2024 | Xarelto |
| Amgen INC. | $381.12 | 2021-2025 | Repatha, Repatha |
| Stryker Corporation | $253.05 | 2021 | |
| Ironwood Pharmaceuticals, INC | $193.32 | 2019-2020 | |
| Abbvie INC. | $99.40 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $97.11 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $35.40 | 2022 | |
| Motiva USA, LLC | $29.04 | 2025 | |
| Fisher Scientific Company L.L.C. | $27.35 | 2024 | Procalcitonin |
| Pfizer INC. | $19.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.